Reviewing Drug Safety
“The Food & Drug Administration has announced a major review of its system for monitoring the safety of drugs already on the market. FDA will sponsor an Institute of Medicine study of the agency’s safety monitoring procedures, and it will set up a formal program to make sure that the views of dissenting agency scientists are heard.”
The Stem Cell Gold Rush:
Scientists around the country who study embryonic stem cells may be mourning four more years of President Bush’s restrictive funding policy, but California scientists are throwing a party, and top researchers in less-funded states are hoping for invitations.
Financial Snapshot For September 2004
In need of a boost.
Biotech: The “safe” drug bet?
“Defensive pharma stocks have struggled while biotechs have flourished. Can this continue?”
Biotech execs have a sense of humor about elusive profits
When Ernst & Young’s annual report on the biotechnology industry last year predicted that as a whole, the industry would turn profitable for the first time in 2008, some long-term industry veterans gave a knowing heard-that-one-before chuckle.
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments